Parkway Neuroscience v. Katz, Abosch, etc., PA

Court of Special Appeals of Maryland·Decided September 30, 2022·No. 0658/21·Published

Opinion

Parkway Neuroscience and Spine Institute, LLC v. Katz, Absoch, Windesheim, Gershman & Freedman, P.A., et al., No. 658, September Term, 2021, Opinion by Adkins, J.

EVIDENCE-EXPERT TESTIMONY: The admissibility of expert testimony is largely within the discretion of the trial court. Such a ruling, however, may be reversed on appeal if it is founded upon an error of law. Judges making discretionary rulings must apply correct legal standards. EVIDENCE—DAUBERT-ROCHKIND: A trial court, in its gatekeeper role under Rochkind and Daubert, acts improperly in excluding the testimony of a qualified certified public accountant testifying about lost profits of an LLC medical practice―on grounds that the expert’s experience with such analysis, although extensive, had only included one medical practice. Any lack of specialized experience is ripe for cross-examination at trial. EVIDENCE—DAUBERT-ROCHKIND: Trial court erred in holding expert testimony unreliable under the Daubert-Rochkind standard after accepting expert’s methodology— the before-and-after method of calculating lost profits. Court’s rationale was (1) using 2015 as the base year; (2) failing to consider changes in insurance reimbursement rates; (3) failing to articulate standards to define economic impact and treat member draws; (4) changing her calculations while the underlying facts remained the same; and (5) failing to offer calculations for profit loss based on variable jury determinations. None of these criticisms addressed methodology, and they were more appropriate for cross-examination and advocacy at trial. EVIDENCE—MARYLAND RULE 5-702: Maryland Rule 5-702 requirement that there is “a sufficient factual basis” supporting the testimony does not justify a trial court’s exclusion of such testimony based upon the correctness of the expert’s conclusions. “[A]nalytical focus should be on principles and methodology. Trial courts may not reject expert testimony simply because they disagree with the conclusions reached by the witness.” Jack B. Weinstein, Weinstein’s Federal Evidence 702.05[2][a] (2d ed. 1997).

Circuit Court for Howard County Case No. C-13-CV-18-000181

REPORTED

IN THE COURT OF SPECIAL APPEALS OF MARYLAND

No. 0658

September Term, 2021

PARKWAY NEUROSCIENCE AND SPINE INSTITUTE, LLC

v.

KATZ, ABOSCH, WINDESHEIM, GERSHMAN & FREEDMAN, P.A., ET AL.

Berger,

Friedman,

Adkins, Sally D.

(Senior Judge, Specially Assigned),

JJ.

Opinion by Adkins, J.

Filed: September 30, 2022

In 1978, the Maryland Court of Appeals adopted the Frye standard for expert testimony, which allowed admission of an expert’s testimony if the basis of that opinion “ha[d] gained general acceptance in the particular field in which it belongs.” Reed v. State, 283 Md. 374, 381 (1978) (quoting Frye v. U.S., 293 F. 1013, 1014 (D.C. Cir. 1923)). Thus, Maryland’s Frye-Reed standard was born. During its tenure as the evidentiary standard for expert testimony admission in Maryland, the Supreme Court adopted a new standard for admission of scientific expert testimony in federal courts, commonly referred to as the Daubert1 standard. Rather than focusing on the general acceptance of the expert’s methodology—like in Frye—the Daubert standard focuses on the reliability of the methodology. See Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 589–90 (1993).

The Supreme Court later expanded the reach of Daubert by applying the standard to admission of expert testimony that was non-scientific in nature. Kumho Tire Co., Ltd. v. Carmichael, 526 U.S. 137, 141 (1999). The supermajority of states had already jumped aboard the Daubert train when Maryland followed suit. In 2020, our Court of Appeals overruled Reed v. State and adopted Daubert as the new standard for admission of expert testimony in Maryland. Rochkind v. Stevenson, 471 Md. 1, 5 (2020). Although Maryland courts had used a “Frye-Reed Plus” standard2—which considered some of the Daubert factors—applying the new Daubert-Rochkind standard and sifting through the thousands

1 Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579 (1993). 2 “In the forty years that followed Reed, Maryland experienced a jurisprudential drift: the Frye-Reed standard announced in 1978 slowly morphed into a “Frye-Reed Plus” standard, implicitly and explicitly relying on and adopting several Daubert principles.” Rochkind v. Stevenson, 471 Md. 1, 5 (2020).

of cases applying the Daubert standard may pose a challenge to circuit courts—as it did in the case at hand.

Parkway Neuroscience and Spine Institute, LLC (“PNSI” or “Appellant”) brought suit against Katz, Abosch, Windesheim, Gershman & Freedman, P.A. (“Katz Abosch”) and Mark Rapson (collectively, “Appellees”)—its previous accounting firm and main accountant. As a remedy, PNSI is seeking lost profits damages. In order to establish lost profits damages, PNSI proffered the expert testimony of Meghan Cardell, a Certified Public Accountant (“CPA”). Appellees moved to exclude Ms. Cardell’s testimony— asserting that the methodology she employed was unreliable—and to strike the lost profits claim. After a Daubert hearing, the Circuit Court for Howard County agreed with Appellees and granted their motion to exclude Ms. Cardell’s testimony and strike the lost profits claim. The circuit court—over PNSI’s opposition—granted the Appellees’ motion for summary judgment on all remaining counts. PNSI timely appealed.

PNSI presents us with the following questions:

1. Did the Trial Court Abuse its Discretion in Granting Defendants’

Renewed Motion to Strike Plaintiff’s Lost Profits Claim and Exclude Plaintiff’s Experts Based on New Daubert Standard and Barring Meghan Cardell from Presenting Expert Testimony Regarding PNSI’s Lost Profits?

2. Did the Trial Court Erroneously Conclude that Ms. Cardell was not Qualified to Render an Expert Opinion Regarding the Lost Profits of a Medical Practice?

3. Did the Trial Court Erroneously Conclude that Ms. Cardell’s Testimony Would Not Assist the Trier of Fact?

For the following reasons, we reverse.

FACTS AND PROCEDURAL HISTORY PNSI is a mixed-specialty medical practice whose practitioners provide treatment for brain, spine, and peripheral nervous system disorders. Starting in 2011, PNSI began to expand its operation with the hiring of more physicians and support staff. Between 2013 and 2014, PNSI had ten physician members who owned the practice. Since none of the members had the necessary background in finance and accounting, PNSI entered into a written agreement in October 2013 with Katz Abosch to provide tax, accounting, “and financial guidance and direction to help PNSI continue to grow its practice.”

Appellee, Mark Rapson, is a CPA and Chair of Katz Abosch’s Medical Services Group. Mr. Rapson—assisted by the CEO of Katz Abosch and another senior accountant—was in charge of PNSI’s account. PNSI normally reconciled its books at the end of the year, so Appellees allegedly agreed to prepare the reconciliation beginning at the end of 2013. According to Appellant, Katz Abosch recommended that PNSI wait to make its end-of-year reconciliation payments until October 2014. At that time PNSI paid four members a total of $422,897 in reconciliation payments. PNSI alleged that Katz Abosch and Mr. Rapson failed to properly evaluate PNSI’s financial position before making this recommendation.

“Between 2012 and 2014, PNSI received payments totaling over $400,000 as part of the Medicare and Medicaid Electronic Health Record (EHR) Incentive Program,” which are also referred to as meaningful use payments. These meaningful use payments are subject to audit and recovery. Allegedly on the advice of Katz Abosch and Rapson, PNSI deposited the meaningful use payments in PNSI’s general funds for member distribution.

Free access — add to your briefcase to read the full text and ask questions with AI

Parkway Neuroscience v. Katz, Abosch, etc., PA, (Md. Ct. App. 2022).

Parkway Neuroscience v. Katz, Abosch, etc., PA (Parkway Neuroscience v. Katz, Abosch, etc., PA) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Riegel v. Medtronic, Inc.
451 F.3d 104 (Second Circuit, 2006)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
General Electric Co. v. Joiner
522 U.S. 136 (Supreme Court, 1997)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Cummings v. Standard Register Co.
265 F.3d 56 (First Circuit, 2001)
Mark A. Smith v. Ford Motor Company
215 F.3d 713 (Seventh Circuit, 2000)
Janopoulos v. Harvey L. Walner & Associates, Ltd.
866 F. Supp. 1086 (N.D. Illinois, 1994)
Gannon v. United States
571 F. Supp. 2d 615 (E.D. Pennsylvania, 2007)
Hughes v. Carter
204 A.2d 566 (Court of Appeals of Maryland, 1964)
Smolow v. Hafer
513 F. Supp. 2d 418 (E.D. Pennsylvania, 2007)
Reed v. State
391 A.2d 364 (Court of Appeals of Maryland, 1978)
Jacobs v. Flynn
749 A.2d 174 (Court of Special Appeals of Maryland, 2000)
Marksman Partners, L.P. v. Chantal Pharmaceutical Corp.
927 F. Supp. 1297 (C.D. California, 1996)
Chapin v. a & L PARTS, INC.
732 N.W.2d 578 (Michigan Court of Appeals, 2007)
Giant Food, Inc. v. Booker
831 A.2d 481 (Court of Special Appeals of Maryland, 2003)
Blackwell v. Wyeth
971 A.2d 235 (Court of Appeals of Maryland, 2009)
Astra Aktiebolag v. Andrx Pharmaceuticals, Inc.
222 F. Supp. 2d 423 (S.D. New York, 2002)
Ameristar Jet Charter, Inc. v. Dodson International Parts, Inc.
155 S.W.3d 50 (Supreme Court of Missouri, 2005)